"Shattuck Labs has submitted an IND application for its first-in-class IBD treatment, SL-325, with a Phase 1 trial expected to start in Q3 2025, supported by $103 million in funding that extends its operational runway to 2029. However, the company faces risks related to clinical trial outcomes and market competition, contributing to a cautious sentiment reflected in its recent performance."